Newsroom

FORT MILL, S.C.--(BUSINESS WIRE)--Sunbelt Rentals Holdings, Inc. (NYSE: SUNB; LSE: SUNB) (“the company”), a leader in the equipment rental industry, today announced it will hold its second quarter fiscal year 2027 results call on Tuesday, December 8, 2026, at 8:30 a.m. ET. The call will be webcast live at ir.sunbeltrentals.com and a replay will be available shortly after the call concludes. The company’s second quarter fiscal year 2027 results press release will be posted on the company’s inves...

BEACHWOOD, Ohio--(BUSINESS WIRE)--Retail Value Inc. to Make Final Liquidating Distribution...

IRVINE, Calif.--(BUSINESS WIRE)--Boot Barn Holdings, Inc. (NYSE: BOOT) today announced its participation in the following investor conference: Stephens 28th Annual Investment Conference Date: Tuesday, November 17, 2026 Fireside Chat Webcast: 10:30 am Eastern Time The fireside chat will be webcast live over the internet and can also be accessed at http://investor.bootbarn.com. An online archive will be available for a period of 90 days following the fireside chat. About Boot Barn Boot Barn is th...

SEATTLE--(BUSINESS WIRE)--F5, Inc. (NASDAQ: FFIV), the global leader in delivering and securing every app and API, today announced that it will participate in the 2026 RBCCM Global Technology, Internet, Media & Telecommunications Conference. F5’s presentation will be webcast live on Wednesday, November 18, 2026, at 10:00 a.m. ET. Interested attendees can access the live webcast via the Events & Presentations tab within the Investor Relations section of f5.com or via this link. An archiv...

CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that management will participate in the following investor conference(s): Management will host one-on-one investor meetings and participate in a fireside chat at Piper Sandler’s 38th Annual Healthcare Conference held at the Lotte Hotel in New York on December 1, 2026 at 4:00pm ET. Management will present to inve...

VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing and commercializing novel therapeutics for debilitating neurodegenerative disorders, today reported financial results for the third quarter ended September 30, 2026, and provided a business update. “The third quarter was our strongest quarter since the launch of ZUNVEYL, the first new oral Alzheimer’s treatment...

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx to Participate in Upcoming Investor Conferences...

ST. LOUIS--(BUSINESS WIRE)--Build-A-Bear Workshop, Inc. (NYSE: BBW) announced today that its Board of Directors declared a quarterly cash dividend of $0.23 per share of issued and outstanding common stock. The dividend will be paid on January 7, 2027, to all stockholders of record as of November 25, 2026. About Build-A-Bear Founded in 1997, Build‑A‑Bear is a leading global retailtainment brand on a mission to add a little more heart to life. At Build-A-Bear, guests are invited to create persona...

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced updated results from the pivotal Cohort 1 of its ongoing, Phase 2 LEGEND trial of detalimogene voraplasmid (also known as detalimogene). Data from Cohort 1, which enrolled 125 patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or...

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN) (“enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced the appointments of Erik T. Goluboff, MD, MBA as Chief Medical Officer and Jason Duncan as Chief Legal and Administrative Officer, effective November 9, 2026. enGene's lead investigational candidate, detalimogene voraplasmid (detalimogene) is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes...